-
Mashup Score: 7
Rachna Shroff, MD, MS, University of Arizona College of Medicine, Tucson, AZ, discusses the latest developments in the targeted therapies…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6
A new personalized cancer treatment can radically improve the outlook for some patients with bile duct cancer, finds an international multicenter trial involving researchers at UCL and University College London Hospitals NHS Trust (UCLH).
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
New precision therapy for #bileductcancer extends #patients' lives @uclnews @nejm https://t.co/AY7fMGLYgn
-
-
Mashup Score: 1
On September 2, 2022, durvalumab was approved for use in combination with gemcitabine/cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind TOPAZ-1 trial (NCT03875235), in which 685 patients with no previous systemic therapy for advanced disease were randomly assigned to…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the Clinic: Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer https://t.co/JRgerO5NaD #hpbcsm #oncology #bileductcancer
-
-
Mashup Score: 0FDA Grants Accelerated Approval to Futibatinib for Previously Treated Patients With FGFR2-Mutated Cholangiocarcinoma - The ASCO Post - 2 year(s) ago
By The ASCO Post Staff Posted: 10/3/2022 10:25:00 AM Last Updated: 10/3/2022 10:59:52 AM On September 30, the U.S. Food and Drug Administration (FDA) granted accelerated approval to futibatinib (Lytgobi) for adults with previously treated, unresectable, locally advanced or metastatic intrahepatic…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA Grants Accelerated Approval to Futibatinib for Previously Treated Patients With FGFR2-Mutated Cholangiocarcinoma https://t.co/0Z8Qc7CETq #oncology @FDAOncology #hpbcsm #bileductcancer #genetics
-
-
Mashup Score: 1Study Examines How Genetic Mutations May Contribute to the Development of Cholangiocarcinoma - The ASCO Post - 2 year(s) ago
By The ASCO Post Staff Posted: 9/2/2022 10:59:00 AM Last Updated: 9/2/2022 12:04:10 PM A team of researchers from the University of Rochester discovered how certain genetic mutations fuel the growth of cholangiocarcinoma, a rare but aggressive type of malignancy that has been on the rise in the United…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study Examines How Genetic Mutations May Contribute to the Development of Cholangiocarcinoma https://t.co/lWiFfwVUnv #hpbcsm #cholangiocarcinoma #bileductcancer #oncology #genetics
-
-
Mashup Score: 1molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling - 2 year(s) ago
AbstractBackground. Chemotherapies have limited efficacy in pancreatic cancer (PC) and biliary tract cancer (BTC), underscoring the need for new regimens. Recen
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
In @JNCI_Now: The molecular landscape of #PancreaticCancer & #BileDuctCancer for novel targeted therapies from real-world genomic profiling (via @FoundationATCG) https://t.co/d20dqJimEw Key take home: make sure that at least #KRAS wild type & young onset cancers are sequenced!
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guided by #precisiononcology, #researchers at the @OSUCCC_James used #rapidautopsy to show promising clinical activity in a second-line therapy for a rare #bileductcancer. The study found that infigratinib worked well against a fusion gene: https://t.co/Mtnu08buxU https://t.co/BgE9LhONUf
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guided by #precisiononcology, #researchers at the @OSUCCC_James used #rapidautopsy to show promising clinical activity in a second-line therapy for a rare #bileductcancer. The study found that infigratinib worked well against a fusion gene: https://t.co/Mtnu08buxU https://t.co/NHQUdBgjZ2
-
-
Mashup Score: 2Treating early stage bile duct cancer with chemoradiation, liver transplant - Mayo Clinic Cancer Center Blog - 2 year(s) ago
Chemoradiation followed by liver transplant is being used more widely to treat perihilar cholangiocarcinoma, the most common form of bile duct cancer.
Source: Mayo Clinic Cancer Center BlogCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Perihilar #cholangiocarcinoma is a small tumor that can cause big problems. Transplant surgeon Julie Heimbach, M.D., talks about Mayo Clinic's approach to these challenging tumors. #BileDuctCancer @MayoCancerCare https://t.co/LjXJxYHwZ8
-
-
Mashup Score: 4
Combination MHT formulations and oral administrations were associated with increased GBC risk, whereas estrogen-only formulations were associated with a lower CCA risk. MHT formulation and administration should be carefully considered when prescribing.
Source: PubMedCategories: Genetics, Latest HeadlinesTweet-
A study in @HEP_Journal by @ssjac79 in #NCI_InfectionImmunoEpi investigated the associations between different menopausal hormone therapies with #GallbladderCancer and #BileDuctCancer risk. #NCI_Biostatistics https://t.co/3dlTBFp2BH https://t.co/m4rdi6XCCe
-
At #GI23 we spoke with @rachnatshroff who discussed latest treatment strategies for patients with biliary tract cancers 🎥 Watch here: https://t.co/TNUNlxlxBF @ASCO #GIsm #CCA #BileDuctCancer